Search Clinical Trials | Froedtert & MCW

Keyword

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

7 results for "Cancer" and "Gynecologic Cancers" and "Early Phase/Multiple Disease Site Cancers"

A Phase I/II Study of TheraT^® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

This study is to investigate the study drug in patients with a specific type of cancer called human papillomavirus 16-positive (HPV 16+) cancers. HPV 16+ cancers include head and neck, cervical, anal, vaginal, vulvar, and penile cancers. The main goal of the study is to determine whether HB-201 and HB-202 are effective in the treatment of human papillomavirus 16 positive (HPV 16+) confirmed cancers.

Protocol No

HOOKIPA-H-200-001

Sub Category

Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Head and Neck Cancers

Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events

This study is being done to answer the following questions: Why do some patients experience serious side effects from immunotherapies, and why do other patients not experience these side effects? How can we identify these patients and prevent, reduce and treat these side effects more effectively? To answer these questions, it is helpful to have clinical data and samples collected from patients who have experienced these side effects from immunotherapy. For example, by studying blood samples collected before and after side effects occur, researchers can look for markers that may predict ...

Protocol No

ALLIANCE-A151804

Sub Category

Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Protocol No

ACCRU-SC-1601

Sub Category

Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers, Brain and Spine Cancers

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Nonsmall Cell Lung Cancer (NSCLC)

Researchers have found that sometimes the body’s own immune system may slow down or control cancer growth. Sometimes this natural immune system response stops, and the cancer is not killed by the immune system. Research has shown that, in some patients, cancer cells and immune cells start to express signals that stop the body’s immune system from killing the cancer. New drugs being developed are designed to block these signals and to increase the immune response. Durvalumab and tremelimumab are two of these drugs. Both drugs are antibodies (proteins that are produced by the body’s defense system). Durvalumab given by itself or with tremelimumab may boost the ability of your immune system to detect and fight cancer. Each of these drugs targets a different signal. Durvalumab targets a signal on cancer cells called Programmed Cell Death Ligand 1 (PD-L1) and tremelimumab targets a signal on immune cells called Cytotoxic T-Lymphocyte-associated Antigen 4 (CTLA-4). It is hoped that by blocking these signals, the immune cells will once again be able to prevent or slow down cancer growth.

The vaccine, BI 1361849, also works by stimulating the body’s immune system to fight and destroy cancer cells. There are six different ingredients in the vaccine that each produce a different antibody response to tumor cells. The vaccine is given through an injection into your skin.

Protocol No

LUDWIG-LUD2014-012-VAC

Sub Category

Early Phase/Multiple Disease Site Cancers, Thoracic Cancers

A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

his clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients.

Protocol No

CYTEIR-CYT-0851-01-REFMAL639

Sub Category

Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Sarcoma, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve symptoms of cancer.

Protocol No

NGM-18-0402

Sub Category

Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Protocol No

TORAY-950P1V02

Sub Category

Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers